NCT00322868View on ClinicalTrials.gov

Safety and Efficacy of Pioglitazone as an Anti-inflammatory for the Treatment of Cystic Fibrosis (CF) Lung Disease

NACompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

April 30, 2006

Primary Completion Date

December 31, 2006

Study Completion Date

April 30, 2007

Conditions
Cystic Fibrosis
Interventions
DRUG

pioglitazone

All subjects treated for 28 days with pioglitazone, 30 mg orally, once daily.

Trial Locations (1)

44106

Rainbow Babies and Children's Hospital, Cleveland

All Listed Sponsors
collaborator

Cystic Fibrosis Foundation

OTHER

lead

University Hospitals Cleveland Medical Center

OTHER

NCT00322868 - Safety and Efficacy of Pioglitazone as an Anti-inflammatory for the Treatment of Cystic Fibrosis (CF) Lung Disease | Biotech Hunter | Biotech Hunter